Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Shuttle Pharmaceuticals Holdings, Inc. amended Amendment Agreement to the Securities Purchase Agreement dated January 11, 2023 with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B valued at Amended the Transaction Documents to remove a provision in the Alto Warrant, stipulated issuance of (effective 2023-05-10).
- Action
- amendment
- Agreement
- equity purchase
- Counterparty
- Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
- Value
- Amended the Transaction Documents to remove a provision in the Alto Warrant, stipulated issuance of
- Effective
- 2023-05-10
Exact text from the filing
On May 10, 2023, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an amendment agreement (the “Amendment Agreement”) to the Securities Purchase Agreement, originally dated January 11, 2023 (the “SPA”), between the Company, Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (“Alto”), in its capacity as the registered holder of a $4.3 million convertible note (the “Alto Note”) and warrant to purchase 1,018,079 shares of common stock (the “Alto Warrant”) issued by the Company, and the Company’s wholly owned subsidiary, Shuttle Pharmaceuticals, Inc., as guarantor (“Shuttle Pharma”). (The Alto Note, Alto Warrant and the SPA are referred to herein as the “Transaction Documents”). Under the Amendment Agreement, the Company and Alto amended the Transaction Documents as follows: (i) amended and restated Section 2 of the Alto Warrant so as to remove a provision that would have potentially required an adjustment to the number of warrant s
View on SEC.gov